Valuation : Immunome, Inc.

Market Cap 3.13B 2.7B 2.53B 2.31B 4.35B 299B 4.36B 30.02B 11.71B 151B 11.76B 11.5B 501B P/E 2026 *
-11.5x
P/E 2027 * -10.5x
Enterprise Value 2.89B 2.49B 2.33B 2.13B 4.01B 276B 4.02B 27.68B 10.8B 139B 10.84B 10.61B 462B EV / Sales 2026 *
8,663x
EV / Sales 2027 * 54x
Free-Float
93.42%
Yield 2026 *
-
Yield 2027 * -
1 day-4.50%
1 week-3.33%
Current month+21.13%
1 month+19.45%
3 months+26.29%
6 months+24.13%
Current year+28.35%
1 week 27.4
Extreme 27.4
29.72
1 month 22.12
Extreme 22.12
30.06
Current year 17.83
Extreme 17.83
30.06
1 year 8.66
Extreme 8.665
30.06
3 years 5.15
Extreme 5.1501
30.96
5 years 2.09
Extreme 2.09
30.96
10 years 2.09
Extreme 2.09
63.78
Manager TitleAgeSince
Chief Executive Officer 65 2023-10-01
Director of Finance/CFO 36 2024-01-01
Chief Tech/Sci/R&D Officer 58 2024-06-26
Director TitleAgeSince
Director/Board Member 55 2016-12-31
Chairman 65 2023-10-01
Director/Board Member 58 2023-10-01
Date Insider Type Main position Quantity % Market Cap.
8/12/26 Sell

Director

-11,048 0.0098%
8/6/26 Other

Director

0 0%
8/4/26 Fiscal year

Executive/Senior Manager

271,848 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
-4.50%-3.33%+189.91%+339.71% 3.13B
-1.59%-3.35%+52.37%+91.62% 69.54B
-2.03%+1.53%+44.83%+88.77% 64.97B
-3.57%+0.49%+35.74%+10.62% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-1.23%+0.90%+29.90%-19.28% 19.98B
-3.36%-4.93%+2.30%+549.93% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.94%-2.07%+67.28%+205.09% 28.51B
Weighted average by Cap. -2.60%-1.52%+51.87%+151.38%

Financials

2026 *2027 *
Net sales 333K 287K 269K 246K 463K 31.86M 465K 3.2M 1.25M 16.08M 1.25M 1.22M 53.32M 55.56M 47.87M 44.89M 40.98M 77.19M 5.31B 77.44M 533M 208M 2.68B 209M 204M 8.89B
Net income -273M -235M -220M -201M -379M -26.08B -380M -2.62B -1.02B -13.17B -1.02B -1B -43.66B -316M -273M -256M -233M -440M -30.25B -441M -3.03B -1.18B -15.27B -1.19B -1.16B -50.63B
Net Debt -244M -210M -197M -180M -338M -23.28B -340M -2.34B -911M -11.75B -915M -895M -38.97B -132M -113M -106M -97.04M -183M -12.57B -183M -1.26B -492M -6.35B -494M -483M -21.05B
Logo Immunome, Inc.
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Employees
247
Date Price Change Volume
26-08-28 US$27.57 -4.50% 784,509
26-08-27 US$28.87 +0.42% 1,055,468
26-08-26 US$28.75 -2.16% 559,029
26-08-25 US$29.39 +4.91% 1,928,775
26-08-24 US$28.01 -1.79% 1,355,475
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
27.57USD
Average target price
36.31USD
Spread / Average Target
+31.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNM Stock